FDA grants marketing approval for ripretinib (Qinlock) for 4th line treatment of advanced gastrointestinal stromal tumours

Approval for this kinase inhibitor is based on positive results from INVICTUS phase 3 study in 129 patients, whose previous therapies have included at least imatinib, sunitinib, and regorafenib, which achieved primary endpoint of improved PFS (6.3 vs 1.0 months with placebo).

Source:

US Food and Drug Administration